@Dr_M_Tejani@NRGonc@VanMorrisMD@skopetz@TGeorgeMD@guardant Unfortunate for patients, but a great opportunity to learn what resulted in higher than expected false+. cfDNA epigenomic information has the potential to increase sensitivity but we have to better understand specificity. I look forward to the data to better understand.
I have been renting cars from @SixtUSA lately but I am noticing a scam to get you to buy insurance and assigning scratches that are preexisting to customers who do not buy such insurance. Time to stop using SIXT #rentalcar#rentalcarinsurance
Important paper, value in screening at earlier age with MRI with the caveat of FP results. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants https://t.co/jYoH0ElRkb via @JAMAOnc part of @JAMANetwork
@elonmusk Range is a problem especially when driving at higher speeds. So ordered Plaid+ but now will cancel. Will stay with my Model S P85D until meaningful improvement in range, 500+.
Updated analysis of EV201 Cohort 2 (cisplatin ineligible mUC pts post IO). Enfortumab vedotin showed a 51% ORR with 22% CR, and mDoR of 13.8mo, which is very reassuring of the benefit of EV in this population. #ASCO21
Zenocutuzumab in tumors with NRG-1 fusion,especially in pancreatic cancers, is promising. Another tissue agnostic target in cancer with an active agent? #nrg1#ASCO21#ASCO2021#zenocutuzumab
@ALEDIGNUS12 I consider ctDNA response to be of significant value as additional clinical validation data becomes available. Limited data shows ability for early response assessment and relatively robust signal.